PEPGEN INC. Operating Expenses
PEPGEN INC. (PEPG) reported Operating Expenses of $18.94 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-06
- PEPGEN INC. operating expenses for the quarter ending 2026-06-30 was $18.94M, a 20.86% decline year-over-year.
- PEPGEN INC. operating expenses for the quarter ending 2026-03-31 was $18.94M, a 39.52% decline year-over-year.
- PEPGEN INC. operating expenses for the quarter ending 2025-12-31 was $19.70M, a 19.06% decline year-over-year.
- PEPGEN INC. operating expenses for the quarter ending 2025-09-30 was $18.65M, a 19.49% decline year-over-year.
- PEPGEN INC. operating expenses for fiscal 2025 was $93.61M, a 4.22% decline from fiscal 2024.
- PEPGEN INC. operating expenses for fiscal 2024 was $97.74M, a 15.30% increase from fiscal 2023.
- PEPGEN INC. operating expenses for fiscal 2023 was $84.77M, a 24.11% increase from fiscal 2022.
- PEPGEN INC. operating expenses for fiscal 2022 was $68.30M, a 151.95% increase from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $18.94M 10-Q · filed 2026-08-06 | $37.88M 10-Q · filed 2026-08-06 | $57.59M derived: sum of 3 quarters · filed 2026-08-06 | $76.24M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $18.94M 10-Q · filed 2026-05-12 | $38.65M derived: sum of 2 quarters · filed 2026-05-12 | $57.30M derived: sum of 3 quarters · filed 2026-05-12 | $81.23M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $19.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $38.36M derived: sum of 2 quarters · filed 2026-03-04 | $62.29M derived: sum of 3 quarters · filed 2026-08-06 | $93.61M 10-K · filed 2026-03-04 |
| 2025-09-30 | $18.65M 10-Q · filed 2025-11-12 | $42.59M derived: sum of 2 quarters · filed 2026-08-06 | $73.91M 10-Q · filed 2025-11-12 | $98.25M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $23.93M 10-Q · filed 2026-08-06 | $55.25M 10-Q · filed 2026-08-06 | $79.60M derived: sum of 3 quarters · filed 2026-08-06 | $102.77M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $31.32M 10-Q · filed 2026-05-12 | $55.67M derived: sum of 2 quarters · filed 2026-05-12 | $78.84M derived: sum of 3 quarters · filed 2026-05-12 | $109.26M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $24.34M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $47.52M derived: sum of 2 quarters · filed 2026-03-04 | $77.94M derived: sum of 3 quarters · filed 2026-03-04 | $97.74M 10-K · filed 2026-03-04 |
| 2024-09-30 | $23.17M 10-Q · filed 2025-11-12 | $53.60M derived: sum of 2 quarters · filed 2025-11-12 | $73.39M 10-Q · filed 2025-11-12 | $94.20M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $30.43M 10-Q · filed 2025-08-07 | $50.22M 10-Q · filed 2025-08-07 | $71.03M derived: sum of 3 quarters · filed 2025-08-07 | $95.81M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $19.80M 10-Q · filed 2025-05-08 | $40.61M derived: sum of 2 quarters · filed 2025-05-08 | $65.39M derived: sum of 3 quarters · filed 2025-05-08 | $86.53M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $20.81M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-24 | $45.59M derived: sum of 2 quarters · filed 2025-02-24 | $66.73M derived: sum of 3 quarters · filed 2025-02-24 | $84.77M 10-K · filed 2025-02-24 |
| 2023-09-30 | $24.78M 10-Q · filed 2024-11-07 | $45.92M derived: sum of 2 quarters · filed 2024-11-07 | $63.95M 10-Q · filed 2024-11-07 | $81.17M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $21.14M 10-Q · filed 2024-08-08 | $39.17M 10-Q · filed 2024-08-08 | $56.39M derived: sum of 3 quarters · filed 2024-08-08 | $75.94M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $18.03M 10-Q · filed 2024-05-14 | $35.24M derived: sum of 2 quarters · filed 2024-05-14 | $54.80M derived: sum of 3 quarters · filed 2024-05-14 | $72.44M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $17.21M derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-03-29 | $36.77M derived: sum of 2 quarters · filed 2024-03-29 | $54.41M derived: sum of 3 quarters · filed 2024-03-29 | $68.30M 10-K/A · filed 2024-03-29 |
| 2022-09-30 | $19.55M 10-Q · filed 2023-11-08 | $37.20M derived: sum of 2 quarters · filed 2023-11-08 | $51.09M 10-Q · filed 2023-11-08 | $58.30M derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | $17.64M 10-Q · filed 2023-08-08 | $31.53M 10-Q · filed 2023-08-08 | $38.74M derived: sum of 3 quarters · filed 2023-08-08 | $46.82M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $13.89M 10-Q · filed 2023-05-11 | $21.10M derived: sum of 2 quarters · filed 2023-05-11 | $29.18M derived: sum of 3 quarters · filed 2023-05-11 | $34.37M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $7.21M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $15.29M derived: sum of 2 quarters · filed 2023-03-23 | $20.48M derived: sum of 3 quarters · filed 2023-03-23 | $27.11M 10-K · filed 2023-03-23 |
| 2021-09-30 | $8.08M 10-Q · filed 2022-11-10 | $13.27M derived: sum of 2 quarters · filed 2022-11-10 | $19.90M 10-Q · filed 2022-11-10 | |
| 2021-06-30 | $5.19M 10-Q · filed 2022-08-12 | $11.82M 10-Q · filed 2022-08-12 | ||
| 2021-03-31 | $6.63M 10-Q · filed 2022-06-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |